MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2025.115637

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2025

Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.

Caillot Raphaëlle, Blom Astrid, Lebbé Céleste, Da Meda Laetitia, Boileau Marie, Dutriaux Caroline, Guillon Benoit, Granel-Brocard Florence, Viguier Manuelle, Lesage Candice, Nardin Charlée, Mansard Sandrine, Charpentier Clément, Zehou Ouidad, Gaudy-Marqueste Caroline, Legoupil Delphine, Minart Benoit, Kieny Alice, Montaudié Henri, L'orphelin Jean-Matthieu, Quéreux Gaelle, Le Corre Yannick, Robert Caroline, Mortier Laurent, Saiag Philippe, Samimi Mahtab

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Merkel cell carcinoma (MCC) is an aggressive skin cancer causing distant metastases in 30 % of cases but rarely involving the brain. PD-1/PD-L1 inhibitors constitute the standard treatment of advanced MCC but their impact on brain metastases is unknown.

METHODS

This retrospective study included MCC patients with central nervous system (CNS) metastases from the French CARADERM registry and the Groupe de Cancérologie Cutanée network. Primary objective was to assess CNS metastases incidence. Secondary objectives included response and survival.

RESULTS

Among 1056 MCC patients, CNS metastases incidence was 0.3 % at baseline and 2.6 % throughout the disease course, reaching 7.0 % in stage IV patients. In 37 patients with CNS metastases, median time from diagnosis to CNS metastases was 15.7 months. Extra-CNS metastases preceded CNS involvement (n = 23) with a median delay of 7.3 months. PD-1/PD-L1 inhibitors were administered before (n = 20) and/or after (n = 23) CNS metastases onset. Intra-cranial responses (n = 15) occurred regardless of prior treatment before CNS metastases. Most (9/15) occurred following stereotactic radiosurgery (SRS) plus immunotherapy, with longer median response duration (15.3 months) versus other treatments (5.1 months). Of prior PD-1/PD-L1 complete responders, 4/6 achieved intracranial response. Median OS and PFS after CNS metastases were 6.6 months and 4.7 months, respectively. PD-1/PD-L1 inhibitors and SRS were associated with improved survival in univariate analysis.

CONCLUSION

CNS metastases are rare, late, and often fatal. PD-1/PD-L1 inhibitors with SRS are likely to constitute the optimal treatment. The quality of response to PD-1/PD-L1 inhibitors prior to CNS metastases predicts intracranial disease control.

Для цитирования: Caillot Raphaëlle, Blom Astrid, Lebbé Céleste, Da Meda Laetitia, Boileau Marie, Dutriaux Caroline, Guillon Benoit, Granel-Brocard Florence, Viguier Manuelle, Lesage Candice, Nardin Charlée, Mansard Sandrine, Charpentier Clément, Zehou Ouidad, Gaudy-Marqueste Caroline, Legoupil Delphine, Minart Benoit, Kieny Alice, Montaudié Henri, L'orphelin Jean-Matthieu, Quéreux Gaelle, Le Corre Yannick, Robert Caroline, Mortier Laurent, Saiag Philippe, Samimi Mahtab. Brain metastases from Merkel cell carcinoma: A nationwide retrospective study.. European journal of cancer (Oxford, England : 1990). 2025. DOI: 10.1016/j.ejca.2025.115637.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.